This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01587/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01587/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01587/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01587/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB01587/identifier/wikipedia/
n16http://linked.opendata.cz/ontology/sukl/drug/
n17http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01587/identifier/pharmgkb/

Statements

Subject Item
n2:DB01587
rdf:type
n3:Drug
n3:description
Ketazolam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Ketazolam is not approved for sale in the United States or Canada.
n3:group
approved
n3:halfLife
26-200 hours
n3:indication
Ketazolam could be used for the treatment of anxiety. In approved countries, it is indicated for the treatment of anxiety, tension, irritability and similar stress related symptoms.
owl:sameAs
n6:DB01587 n10:DB01587
dcterms:title
Ketazolam
adms:identifier
n8:PA164749385 n9:Ketazolam n12:DB01587 n13:31110 n14:33746 n15:46507008
n3:mechanismOfAction
Benzodiazepines share a similar chemical structure and their effects in humans are mainly produced by the allosteric modification of a specific kind of neurotransmitter receptor, the GABAA receptor, which increases the conductance of this inhibitory channel; this results in the various therapeutic effects as well as adverse effects of benzodiazepines. Binding of benzodiazepines to this receptor complex promotes binding of GABA, which in turn increases the conduction of chloride ions across the neuronal cell membrane. This increased conductance raises the membrane potential of the neuron resulting in inhibition of neuronal firing. In addition, different GABAA receptor subtypes have varying distributions within different regions of the brain and therefore control distinct neuronal circuits. Hence, activation of different GABAA receptor subtypes by benzodiazepines may result in distinct pharmacological actions.
n3:routeOfElimination
Diazepam and its metabolites are excreted mainly in the urine, predominantly as their glucuronide conjugates.
n3:synonym
U-28774 Ketazolam
n3:toxicity
Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.
n3:foodInteraction
Take with food. Avoid excessive quantities of coffee or tea (caffeine). Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product. Avoid alcohol
n3:synthesisReference
U.S. Patent 3,575,965.
n3:IUPAC-Name
n4:271B589C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B58A2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B58A1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B589E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B589F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B58A0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B589A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5898-363D-11E5-9242-09173F13E4C5 n4:271B589B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5899-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:N05BA10
n3:H-Bond-Acceptor-Count
n4:271B58A8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B58A9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B58A3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B58A4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B58A6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B58A5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B58A7-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
27223-35-4
n3:category
n3:Bioavailability
n4:271B58AE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B58B0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B58B1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B58B2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B58AD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B58AC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B58AF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B589D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B58AA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B58AB-363D-11E5-9242-09173F13E4C5